US20060252725A1 - Use of prebiotics for preventing or treating oxidation stress - Google Patents
Use of prebiotics for preventing or treating oxidation stress Download PDFInfo
- Publication number
- US20060252725A1 US20060252725A1 US10/539,632 US53963205A US2006252725A1 US 20060252725 A1 US20060252725 A1 US 20060252725A1 US 53963205 A US53963205 A US 53963205A US 2006252725 A1 US2006252725 A1 US 2006252725A1
- Authority
- US
- United States
- Prior art keywords
- fructose
- approximately
- fos
- oxidative stress
- fructosyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 21
- 230000003647 oxidation Effects 0.000 title description 2
- 238000007254 oxidation reaction Methods 0.000 title description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 70
- 239000005715 Fructose Substances 0.000 claims abstract description 44
- 230000036542 oxidative stress Effects 0.000 claims abstract description 32
- 229930091371 Fructose Natural products 0.000 claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 27
- 238000002360 preparation method Methods 0.000 claims abstract description 26
- 235000013376 functional food Nutrition 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 229920001542 oligosaccharide Polymers 0.000 claims description 10
- 150000002482 oligosaccharides Chemical class 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 244000068988 Glycine max Species 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 238000006116 polymerization reaction Methods 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- 229920002670 Fructan Polymers 0.000 claims description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 5
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 5
- 150000008163 sugars Chemical class 0.000 claims description 5
- QNTKVQQLMHZOKP-NEJDVEAASA-N (2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-2-[[(2r,3s,4s,5r)-2-[[(2r,3s,4s,5r)-2-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]- Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QNTKVQQLMHZOKP-NEJDVEAASA-N 0.000 claims description 3
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 claims description 3
- VAWYEUIPHLMNNF-OESPXIITSA-N 1-kestose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VAWYEUIPHLMNNF-OESPXIITSA-N 0.000 claims description 3
- GIUOHBJZYJAZNP-DVZCMHTBSA-N 1-kestose Natural products OC[C@@H]1O[C@](CO)(OC[C@]2(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)O[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O GIUOHBJZYJAZNP-DVZCMHTBSA-N 0.000 claims description 3
- FLDFNEBHEXLZRX-DLQNOBSRSA-N Nystose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FLDFNEBHEXLZRX-DLQNOBSRSA-N 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 230000002225 anti-radical effect Effects 0.000 claims description 3
- VAWYEUIPHLMNNF-UHFFFAOYSA-N kestotriose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 VAWYEUIPHLMNNF-UHFFFAOYSA-N 0.000 claims description 3
- FLDFNEBHEXLZRX-UHFFFAOYSA-N nystose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OCC2(OC3C(C(O)C(O)C(CO)O3)O)C(C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 FLDFNEBHEXLZRX-UHFFFAOYSA-N 0.000 claims description 3
- 230000003712 anti-aging effect Effects 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 abstract description 10
- 235000014633 carbohydrates Nutrition 0.000 abstract description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 16
- 229920002472 Starch Polymers 0.000 description 14
- 235000019698 starch Nutrition 0.000 description 14
- 239000008107 starch Substances 0.000 description 14
- 235000005911 diet Nutrition 0.000 description 13
- 230000037213 diet Effects 0.000 description 12
- 235000019165 vitamin E Nutrition 0.000 description 9
- 239000011709 vitamin E Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 229930003427 Vitamin E Natural products 0.000 description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 229940046009 vitamin E Drugs 0.000 description 8
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 241000894007 species Species 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000003244 pro-oxidative effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- RNBGYGVWRKECFJ-ARQDHWQXSA-N beta-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ARQDHWQXSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 229950005392 fosfructose Drugs 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 230000006099 transfructosylation Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- YJGAQZSJEQXYGO-JTIPTFDKSA-N (3S,4R,5R)-1-[(3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OCC1([C@@H](O)[C@H](O)[C@H](O1)CO)C(O)C(=O)[C@@H](O)[C@H](O)[C@H](O)CO YJGAQZSJEQXYGO-JTIPTFDKSA-N 0.000 description 1
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- ZCLAHGAZPPEVDX-UHFFFAOYSA-N D-panose Natural products OC1C(O)C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC1COC1C(O)C(O)C(O)C(CO)O1 ZCLAHGAZPPEVDX-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229920000884 Isomaltosaccharide Polymers 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012182 cereal bars Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 150000002402 hexoses Chemical group 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- FBJQEBRMDXPWNX-FYHZSNTMSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)C(O)O2)O)O1 FBJQEBRMDXPWNX-FYHZSNTMSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- ZCLAHGAZPPEVDX-MQHGYYCBSA-N panose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ZCLAHGAZPPEVDX-MQHGYYCBSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- a subject of the present invention is the use of prebiotics for the preparation of food preparations, functional foods, or pharmaceutical compositions intended to prevent or treat oxidative stress.
- Oxidative stress is the result of an imbalance in the organism in favor of pro-oxidant species relative to anti-oxidant species.
- Pro-oxidant species are generally free radicals and in particular oxygenated free radicals.
- the presence of an unpaired electron makes these compounds extremely reactive vis-à-vis the biological macromolecules of the organism; lipids, carbohydrates, proteins and nucleic acids are thus preferred targets of these species.
- the oxidative degradation of these macromolecules leads to many cellular malfunctions.
- the anti-oxidant defenses of the organism use protein systems, such as superoxide dismutase, but also anti-oxidant compounds provided by food, such as vitamins C and E, or other nutrients, such as carotenoids, polyphenols or flavonoids.
- Dietary imbalances can be the origin of oxidative stress.
- the inventors have in particular previously shown that food which is too rich in sugars, and in particular in saccharose (Busserolles et al., 2002a) and fructose (Busserolles et al., 2002b), could cause significant oxidative stress. These pro-oxidant effects are even more significant the lower the content of anti-oxidants in the food is.
- Fructose is a monosaccharide, the consumption of which has greatly increased, either as it is or in the form of saccharose. Because of their low production costs, syrups that are rich in fructose produced from corn are preferably used in sugary drinks. While fructose is naturally present in honey and in fruits where it is associated with many protective micronutrients, the consequences of an unrestricted increase of this carbohydrate in purified form on health are questionable. In fact, fructose has many properties which distinguish it from other sugars and the high intake of this carbohydrate could be responsible for undesirable metabolic effects.
- the modalities for combating oxidative stress generally include the use of anti-radical nutrients having a direct effect on free radicals: carotenes, ascorbic acid (vitamin C), tocopherols (vitamin E), polyphenols (U.S. Pat. No. 6,207,702).
- the present invention results from the inventors demonstrating that prebiotics and more particularly fructooligosaccharides (FOS) can combat the oxidative stress resulting from an excess of fructose in food.
- FOS fructooligosaccharides
- Prebiotics are non-digestible complex carbohydrates broken down by the microorganisms of the intestinal flora and whose breakdown has beneficial health effects for the host. These microorganisms are generally bacteria, and in particular bifidobacteria, which are essentially found in the colon. The beneficial effects provided by said microorganisms can be due to the selective stimulation of the growth of certain species of microorganisms, in particular bifidobacteria, and/or to the release of metabolites originating from the conversion of the prebiotics by the microorganisms.
- oligosaccharides sugar polymers with a degree of polymerization comprised between 2 and 12, classified as complex carbohydrates: oligosaccharides.
- fructans, galactooligosaccharides, xylooligosaccharides, soybean oligosaccharides, gentiooligosaccharides or also isomaltooligosaccharides may be mentioned.
- Fructooligosaccharides are obtained either by hydrolysis of inulin, or by enzymatic synthesis, by transfructosylation from saccharide precursors. They correspond to the general formula Glucosyl-(Fructosyl) n -Fructose or (Fructosyl) m -Fructose where n represents an integer from 1 to 8 and m represents an integer from 1 to 8. In most cases FOS preparations are not homogeneous. They comprise mixtures of chains of variable size.
- the polymers correspond to the formula Glucosyl-(Fructosyl) n -Fructose (1 ⁇ n ⁇ 8)
- the FOS prepared by hydrolysis correspond to the two formulae Glucosyl-(Fructosyl) n -Fructose and/or (Fructosyl) m -Fructose (1 ⁇ n ⁇ 8 and 1 ⁇ m ⁇ 8).
- the FOS in particular comprise short-chain fructooligosaccharides, synthesized by transfructosylation, whose degree of polymerization is less than 6, and in particular short-chain FOS with 2, 3 or 4 fructose units such as 1-kestose, nystose and fructosyl-nystose.
- Fructans are polymers in which the fructosyl-fructose type bonds predominate.
- the galactooligosaccharides are formed by 2 to 6 hexose units, they mainly comprise galactose as a base unit. They are synthesized by the action of ⁇ -galactosidase on lactose.
- Xylooligosaccharides originate from the hydrolysis of xylan, they are constituted by xylose.
- Soybean oligosaccharides are extracted from soybean, these are mainly oligosaccharide mixtures comprising from 1 to 4 osidic units, the main constituents being raffinose and stachyose.
- Gentiooligosaccharides are polymers originating from the digestion of starch, in which most of the bond has the ⁇ -glucopyranosyl-(1 ⁇ 6)-glucopyranose form.
- Isomaltosaccharides are also glucose polymers which originate from the hydrolysis of starch, these are mixtures of isomaltose, panose, isomaltotriose and other branched polymers containing 4 or 5 glucose units.
- the inventors have shown that the addition of prebiotics to the food intake, advantageously the addition of FOS, allowed a reduction in oxidative stress due in particular to a diet rich in sugars, and in particular fructose.
- the purpose of the invention is to provide new means for preventing or treating oxidative stress.
- a subject of the invention is the use of prebiotics for the preparation of food preparations, functional foods, or pharmaceutical compositions intended to prevent or treat oxidative stress.
- a subject of the invention is more particularly the above-mentioned use of at least one oligosaccharide chosen from:
- the invention more particularly relates to the above-mentioned use of fructooligosaccharides (FOS) of general formula Glucosyl-(Fructosyl) n -Fructose or (Fructosyl) m -Fructose where n represents an integer from 1 to 8, in particular from 1 to 5, and m represents an integer from 1 to 8, in particular from 1 to 5, such as short-chain FOS, 1-kestose, nystose or fructosyl-nystose.
- FOS fructooligosaccharides
- a subject of the invention is also the use of prebiotics in the context of the prevention or treatment of oxidative stress linked to the consumption of sugars.
- the invention more particularly relates to the use of prebiotics in the context of the prevention or treatment of oxidative stress linked to the consumption of fructose.
- the invention in particular relates to the use of prebiotics in the context of the prevention or treatment of oxidative stress due to a consumption of fructose in food greater than approximately 50 g/day on average.
- the invention also relates to the use of prebiotics, where said prebiotics are administered at a daily dose of approximately 1 g to approximately 20 g, in particular approximately 2 g to approximately 17 g, in particular approximately 5 g to approximately 15 g.
- a subject of the invention is also the use of prebiotics as compounds with an anti-radical effect in the context of the prevention or treatment of oxidative stress.
- a subject of the invention is also the use of prebiotics as compounds with an anti-aging effect linked to an effect which protects the cells of the organism against the action of free radicals.
- the invention also relates to any food preparation comprising simple carbohydrates in combination with prebiotics.
- the invention more particularly relates to a food preparation comprising:
- the food preparation of the invention is such that the proportion of prebiotics represents at least 5% by weight of the quantity of simple carbohydrates present in said preparation.
- the invention in particular relates to a food preparation in which the proportion by weight of fructooligosaccharides (FOS) relative to the quantity of fructose present in said preparation varies between 10% and 100% and is in particular approximately 15% to approximately 35% and is in particular approximately 20%.
- FOS fructooligosaccharides
- the invention in particular relates to a food preparation comprising a mixture of fructooligosaccharides (FOS), as defined above, comprising 64% Glucosyl-(Fructosyl) n -Fructose and 36% (Fructosyl) m -Fructose with average degrees of polymerization of 4.8.
- FOS fructooligosaccharides
- the invention more particularly relates to a food preparation comprising a mixture of fructooligosaccharides (FOS), as defined above, comprising 64% Glucosyl-(Fructosyl) n -Fructose and 36% (Fructosyl) m -Fructose, with average degrees of polymerization of 4.8, the proportion by weight of said FOS present in said preparation varying between 10% and 100%, and in particular being approximately 15% to approximately 35%, preferably approximately 20%, relative to the quantity of fructose present in said preparation.
- FOS fructooligosaccharides
- the FOS mixture used corresponds to the Raftilose® P 95 preparation from ORAFTI, Thienen, Belgium.
- a subject of the invention is also a food product containing the food preparation defined above, said food product being chosen from a group comprising pastries, confectionary, desserts, drinks, cereal bars, chocolate bars, sweet bars, breakfast cereals, dairy products and food supplements.
- the inventors have shown, in an animal model, that the addition of fructooligosaccharides (FOS) to the food intake allows a reduction in oxidative stress due to a diet enriched in fructose.
- FOS fructooligosaccharides
- the food and distilled water were provided ad libitum.
- the composition of the food rations was as follows (in g/kg): Group Group Group Group A F A/FOS F/FOS Starch 650 — 550 — Fructose — 650 — 550 FOS (Raftilose ® P 95 ) — — 100 100 Casein 200 200 200 200 Corn oil 50 50 50 50 50 Alphacel 50 50 50 50 50 50 50 Methionine D, L 3 3 3 3 3 Choline bitartrate 2 2 2 2 2 2 Mineral mixture (AIN-76) 35 35 35 35 35 Vitamin mixture (AIN-76A) 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
- the AIN-76 and AIN-76A mixtures were provided by ICN Biomedicals, Orsay, France.
- Raftilose® P 95 The FOS (Raftilose® P 95 ) were obtained from ORAFTI, Thienen, Belgium. They were introduced into the food gradually in order to avoid diarrhoea which could occur in response to too rapid an administration of large quantities of this compound.
- Raftilose® P 95 is a mixture of Glucosyl-(Fructosyl) n -Fructose (64%) and of (Fructosyl) m -Fructose (36%) with average degrees of polymerization of 4.8.
- Measurement of TBARS allows evaluation of the level of lipid peroxidation of a sample subjected to an oxidative stress. The greater the value of TBARS the higher the level of oxidative stress.
- the levels of plasma TBARS were determined by spectrofluorometry on an LS 5 device (Perkin Elmer, Norwalk, Conn., USA). A method adapted from Okhawa et al. (1979) was used as previously described (Rayssiguier et al., 1993). The level of the urinary TBARS was measured as described in Lee et al. (1992) and calculated on the basis of a urinary volume of 24 hours. Finally, the measurement of the heart TBARS was based on Ohkawa et al. (1979), they allow the evaluation of the susceptibility of the heart lipids to peroxidation.
- the heart tissues were homogenized on ice at a ratio of 1 g of fresh tissue to 9 ml of KCl 150 mmol/l using a Polytron homogenizer, these homogenates were then subjected to a lipid peroxidation induced by a FeSO 4 (2 ⁇ mol/l)-ascorbate (50 ⁇ mol/l) mixture for 30 minutes in a bath at 37° C. in the absence of oxygen, a 1,1,3,3-tetraethoxypropane control was used; the TBARS were then measured by spectrophotometry (Uvikon 941 plus series, Kontron Instruments, St Quentin en Yvelines, France).
- the TBARS of the Fructose+FOS group are significantly lower than those of the Fructose group and are not significantly different to those of the Starch+FOS group.
- the FOS therefore allow the oxidative stress which is due to the consumption of fructose to be limited.
- the ratio vitamin E/plasma triglycerides reflects the oxidative stress to which an organism has been subjected. The smaller the value of this ratio the greater the level of oxidative stress.
- the plasma concentrations of vitamin E were determined by reversed-phase high performance liquid chromatography on a Kontron series 400 device (Kontron St Quentin en Yvelines, France) using a hexane extract. ⁇ -tocopherol acetate (Sigma) was added to the samples as internal control. The samples were extracted twice with hexane after precipitation of the proteins with ethanol. The extract was dried under nitrogen, dissolved in an ethanol-methylene chloride mixture (65:35, v/v) and injected onto a C 18 column (Nucleosil; 250 mm long, i.d. 46 mm., 5 ⁇ m particles).
- the diet rich in fructose lowers the ratio Vitamin E/TG, which proves the existence of oxidative stress.
- the supplementation with FOS prevents the lowering of this ratio, in other words reduces the oxidative stress which results from consumption of a diet rich in fructose.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to the use of prebiotics for the preparation of food preparations, functional foods, or pharmaceutical compositions for preventing or treating oxidative stress in particular linked to the consumption of fructose. The invention also relates to a food preparation comprising simple carbohydrates, in particular fructose, in combination with prebiotics.
Description
- A subject of the present invention is the use of prebiotics for the preparation of food preparations, functional foods, or pharmaceutical compositions intended to prevent or treat oxidative stress.
- Oxidative stress is the result of an imbalance in the organism in favor of pro-oxidant species relative to anti-oxidant species.
- Pro-oxidant species are generally free radicals and in particular oxygenated free radicals. The presence of an unpaired electron makes these compounds extremely reactive vis-à-vis the biological macromolecules of the organism; lipids, carbohydrates, proteins and nucleic acids are thus preferred targets of these species. The oxidative degradation of these macromolecules leads to many cellular malfunctions.
- The origin of these free radicals is essentially found in the metabolism of oxygen. Most of the oxidative stress originates from the energy metabolism. The final stage of the oxidation of food, namely the mitochondrial respiratory chain, is thus the origin of the formation of oxygenated free radicals. Moreover, during inflammatory reaction, the stimulation of the phagocytes is also accompanied by the formation of free radicals.
- The anti-oxidant defenses of the organism use protein systems, such as superoxide dismutase, but also anti-oxidant compounds provided by food, such as vitamins C and E, or other nutrients, such as carotenoids, polyphenols or flavonoids.
- Dietary imbalances can be the origin of oxidative stress. The inventors have in particular previously shown that food which is too rich in sugars, and in particular in saccharose (Busserolles et al., 2002a) and fructose (Busserolles et al., 2002b), could cause significant oxidative stress. These pro-oxidant effects are even more significant the lower the content of anti-oxidants in the food is.
- Fructose is a monosaccharide, the consumption of which has greatly increased, either as it is or in the form of saccharose. Because of their low production costs, syrups that are rich in fructose produced from corn are preferably used in sugary drinks. While fructose is naturally present in honey and in fruits where it is associated with many protective micronutrients, the consequences of an unrestricted increase of this carbohydrate in purified form on health are questionable. In fact, fructose has many properties which distinguish it from other sugars and the high intake of this carbohydrate could be responsible for undesirable metabolic effects.
- The modalities for combating oxidative stress generally include the use of anti-radical nutrients having a direct effect on free radicals: carotenes, ascorbic acid (vitamin C), tocopherols (vitamin E), polyphenols (U.S. Pat. No. 6,207,702).
- The present invention results from the inventors demonstrating that prebiotics and more particularly fructooligosaccharides (FOS) can combat the oxidative stress resulting from an excess of fructose in food.
- Prebiotics are non-digestible complex carbohydrates broken down by the microorganisms of the intestinal flora and whose breakdown has beneficial health effects for the host. These microorganisms are generally bacteria, and in particular bifidobacteria, which are essentially found in the colon. The beneficial effects provided by said microorganisms can be due to the selective stimulation of the growth of certain species of microorganisms, in particular bifidobacteria, and/or to the release of metabolites originating from the conversion of the prebiotics by the microorganisms.
- At present, the only clearly defined prebiotics are sugar polymers with a degree of polymerization comprised between 2 and 12, classified as complex carbohydrates: oligosaccharides. Thus, apart from fructooligosaccharides whose effects are most documented, fructans, galactooligosaccharides, xylooligosaccharides, soybean oligosaccharides, gentiooligosaccharides or also isomaltooligosaccharides, may be mentioned.
- Fructooligosaccharides (FOS) are obtained either by hydrolysis of inulin, or by enzymatic synthesis, by transfructosylation from saccharide precursors. They correspond to the general formula Glucosyl-(Fructosyl)n-Fructose or (Fructosyl)m-Fructose where n represents an integer from 1 to 8 and m represents an integer from 1 to 8. In most cases FOS preparations are not homogeneous. They comprise mixtures of chains of variable size. Moreover, in the case of the preparation of FOS by enzymatic synthesis, the polymers correspond to the formula Glucosyl-(Fructosyl)n-Fructose (1≦n≦8), while the FOS prepared by hydrolysis correspond to the two formulae Glucosyl-(Fructosyl)n-Fructose and/or (Fructosyl)m-Fructose (1≦n≦8 and 1≦m≦8). The FOS in particular comprise short-chain fructooligosaccharides, synthesized by transfructosylation, whose degree of polymerization is less than 6, and in particular short-chain FOS with 2, 3 or 4 fructose units such as 1-kestose, nystose and fructosyl-nystose.
- Fructans are polymers in which the fructosyl-fructose type bonds predominate.
- The galactooligosaccharides are formed by 2 to 6 hexose units, they mainly comprise galactose as a base unit. They are synthesized by the action of β-galactosidase on lactose.
- Xylooligosaccharides originate from the hydrolysis of xylan, they are constituted by xylose.
- Soybean oligosaccharides are extracted from soybean, these are mainly oligosaccharide mixtures comprising from 1 to 4 osidic units, the main constituents being raffinose and stachyose.
- Gentiooligosaccharides are polymers originating from the digestion of starch, in which most of the bond has the β-glucopyranosyl-(1→6)-glucopyranose form.
- Isomaltosaccharides are also glucose polymers which originate from the hydrolysis of starch, these are mixtures of isomaltose, panose, isomaltotriose and other branched polymers containing 4 or 5 glucose units.
- The inventors have shown that the addition of prebiotics to the food intake, advantageously the addition of FOS, allowed a reduction in oxidative stress due in particular to a diet rich in sugars, and in particular fructose.
- The purpose of the invention is to provide new means for preventing or treating oxidative stress.
- A subject of the invention is the use of prebiotics for the preparation of food preparations, functional foods, or pharmaceutical compositions intended to prevent or treat oxidative stress.
- A subject of the invention is more particularly the above-mentioned use of at least one oligosaccharide chosen from:
-
- fructanes
- fructooligosaccharides (FOS)
- galactooligosaccharides
- xylooligosaccharides
- soybean oligosaccharides
- gentiooligosaccharides
- isomaltooligosaccharides
- as defined above.
- The invention more particularly relates to the above-mentioned use of fructooligosaccharides (FOS) of general formula Glucosyl-(Fructosyl)n-Fructose or (Fructosyl)m-Fructose where n represents an integer from 1 to 8, in particular from 1 to 5, and m represents an integer from 1 to 8, in particular from 1 to 5, such as short-chain FOS, 1-kestose, nystose or fructosyl-nystose.
- A subject of the invention is also the use of prebiotics in the context of the prevention or treatment of oxidative stress linked to the consumption of sugars.
- The invention more particularly relates to the use of prebiotics in the context of the prevention or treatment of oxidative stress linked to the consumption of fructose.
- The invention in particular relates to the use of prebiotics in the context of the prevention or treatment of oxidative stress due to a consumption of fructose in food greater than approximately 50 g/day on average.
- The invention also relates to the use of prebiotics, where said prebiotics are administered at a daily dose of approximately 1 g to approximately 20 g, in particular approximately 2 g to approximately 17 g, in particular approximately 5 g to approximately 15 g.
- A subject of the invention is also the use of prebiotics as compounds with an anti-radical effect in the context of the prevention or treatment of oxidative stress.
- A subject of the invention is also the use of prebiotics as compounds with an anti-aging effect linked to an effect which protects the cells of the organism against the action of free radicals.
- The invention also relates to any food preparation comprising simple carbohydrates in combination with prebiotics.
- The invention more particularly relates to a food preparation comprising:
-
- at least one simple carbohydrate such as fructose or saccharose,
- in combination with one or more oligosaccharides chosen from:
- fructanes
- fructooligosaccharides (FOS)
- galactooligosaccharides
- xylooligosaccharides
- soybean oligosaccharides
- gentiooligosaccharides
- isomaltooligosaccharides
- as defined above.
- Advantageously the food preparation of the invention is such that the proportion of prebiotics represents at least 5% by weight of the quantity of simple carbohydrates present in said preparation.
- The invention in particular relates to a food preparation in which the proportion by weight of fructooligosaccharides (FOS) relative to the quantity of fructose present in said preparation varies between 10% and 100% and is in particular approximately 15% to approximately 35% and is in particular approximately 20%.
- The invention in particular relates to a food preparation comprising a mixture of fructooligosaccharides (FOS), as defined above, comprising 64% Glucosyl-(Fructosyl)n-Fructose and 36% (Fructosyl)m-Fructose with average degrees of polymerization of 4.8.
- The invention more particularly relates to a food preparation comprising a mixture of fructooligosaccharides (FOS), as defined above, comprising 64% Glucosyl-(Fructosyl)n-Fructose and 36% (Fructosyl)m-Fructose, with average degrees of polymerization of 4.8, the proportion by weight of said FOS present in said preparation varying between 10% and 100%, and in particular being approximately 15% to approximately 35%, preferably approximately 20%, relative to the quantity of fructose present in said preparation.
- According to a preferred embodiment, the FOS mixture used corresponds to the Raftilose® P95 preparation from ORAFTI, Thienen, Belgium.
- A subject of the invention is also a food product containing the food preparation defined above, said food product being chosen from a group comprising pastries, confectionary, desserts, drinks, cereal bars, chocolate bars, sweet bars, breakfast cereals, dairy products and food supplements.
- The inventors have shown, in an animal model, that the addition of fructooligosaccharides (FOS) to the food intake allows a reduction in oxidative stress due to a diet enriched in fructose.
- 40 weaned male rats of the Wistar-Han type (IFFA-CREDO; L'Arbresle, France) 6 week old and weighing approximately 150 g were used. The rats were placed in cages with a wire mesh back in a temperature-controlled room (22° C.) with day/night cycles of 12 hours. The animals were treated according to the recommendations of the INRA Ethics Committee, decree No. 87-848.
- First of all the rats were fed following a semi-purified starch-based diet for 7 days: They were then randomly divided into 4 groups of 10 rats: one starch group (A), one fructose group (F), one starch+FOS group (A/FOS) and one fructose+FOS group (F/FOS). They then followed their appropriate diet for 4 weeks.
- The food and distilled water were provided ad libitum. The composition of the food rations was as follows (in g/kg):
Group Group Group Group A F A/FOS F/FOS Starch 650 — 550 — Fructose — 650 — 550 FOS (Raftilose ® P95) — — 100 100 Casein 200 200 200 200 Corn oil 50 50 50 50 Alphacel 50 50 50 50 Methionine D, L 3 3 3 3 Choline bitartrate 2 2 2 2 Mineral mixture (AIN-76) 35 35 35 35 Vitamin mixture (AIN-76A) 10 10 10 10 - The AIN-76 and AIN-76A mixtures were provided by ICN Biomedicals, Orsay, France.
- The FOS (Raftilose® P95) were obtained from ORAFTI, Thienen, Belgium. They were introduced into the food gradually in order to avoid diarrhoea which could occur in response to too rapid an administration of large quantities of this compound. Raftilose® P95 is a mixture of Glucosyl-(Fructosyl)n-Fructose (64%) and of (Fructosyl)m-Fructose (36%) with average degrees of polymerization of 4.8.
- 4 days before sacrifice, the animals were housed individually in stainless steel cages with ad libitum access to the water and food. Urine-samples were recovered 24 hours before sacrifice in 50 ml graduated tubes, the volumes were precisely measured, the samples were then centrifuged and kept at −80° C. until analysis. At the time of sacrifice the rats were weighed, then anesthetized using sodium pentobarbital (intra-peritoneal injection at 40 mg/kg) and killed. The blood was taken from the abdominal aorta and placed in heparinized tubes. The plasma obtained after centrifugation at low speed (2000 g, 15 min) was kept at −80° C. for the biochemical analyses. The heart was rapidly removed then washed in an ice-cooled saline Solution (NaCl 9 g/l), placed in liquid nitrogen and kept at −80° C.
- Two types of measurements well known to a person skilled in the art were then taken in order to determine the intensity of oxidative stress of the animals as a function of their diet: a measurement of the substances reactive to thiobarbituric acid (TBARS) and a measurement of the ratio of the plasma concentrations of vitamin E and triglycerides.
- A statistical analysis of the results was carried out using the Statview program (Abacus Concepts Inc., Berkeley, Calif.). The data were expressed as the average of the results obtained for the 10 animals of each food group±standard deviation. The analysis of the variance (ANOVA; P<0.05) was used in order to determine the main effects (sugar and FOS) and their interactions. The differences were considered to be significant when p<0.05.
- These results indicate that the animals following the fructose diet are subjected to a significantly greater oxidative stress than that of the control animals (subjected to the starch diet) and that the addition of FOS allows significant reduction in the oxidative stress linked to the consumption of fructose.
- Measurement of the Substances Reactive to Thiobarbituric Acid (TBARS)
- Measurement of TBARS allows evaluation of the level of lipid peroxidation of a sample subjected to an oxidative stress. The greater the value of TBARS the higher the level of oxidative stress.
- The levels of plasma TBARS were determined by spectrofluorometry on an LS 5 device (Perkin Elmer, Norwalk, Conn., USA). A method adapted from Okhawa et al. (1979) was used as previously described (Rayssiguier et al., 1993). The level of the urinary TBARS was measured as described in Lee et al. (1992) and calculated on the basis of a urinary volume of 24 hours. Finally, the measurement of the heart TBARS was based on Ohkawa et al. (1979), they allow the evaluation of the susceptibility of the heart lipids to peroxidation. The heart tissues were homogenized on ice at a ratio of 1 g of fresh tissue to 9 ml of KCl 150 mmol/l using a Polytron homogenizer, these homogenates were then subjected to a lipid peroxidation induced by a FeSO4 (2 μmol/l)-ascorbate (50 μmol/l) mixture for 30 minutes in a bath at 37° C. in the absence of oxygen, a 1,1,3,3-tetraethoxypropane control was used; the TBARS were then measured by spectrophotometry (Uvikon 941 plus series, Kontron Instruments, St Quentin en Yvelines, France).
- The results obtained are shown in the following table:
Diet Anovaa Starch Fructose Starch + FOS Fructose + FOS Sugar FOS Sugar × FOS Plasma TBARS 1.94 ± 0.03 2.14 ± 0.07 1.84 ± 0.02 1.96 ± 0.04 <0.01 <0.01 NS nmol/ml Urinary TBARS 11.99 ± 0.50 21.97 ± 1.58 13.40 ± 0.53 15.86 ± 1.19 <0.001 <0.05 <0.001 nmol/24 h Heart TBARS 64.9 ± 4.1 98.8 ± 6.5 73.1 ± 3.5 83.5 ± 4.7 <0.001 NS <0.05 nmol/g of fresh weight
The results are the averages calculated for 10 animals ± standard deviation.
avalue of p for the ANOVA. The results of the ANOVA are significant for p < 0.05, NS. not significant
- The results indicate that the plasma, urinary and heart TBARS are significantly higher for the Fructose group than for the Starch group. The consumption of fructose is therefore responsible for greater oxidative stress than that which is due to the consumption of starch.
- Moreover, the TBARS of the Fructose+FOS group are significantly lower than those of the Fructose group and are not significantly different to those of the Starch+FOS group. The FOS therefore allow the oxidative stress which is due to the consumption of fructose to be limited.
- Measurement of the Plasma Ratio of Vitamin E and Triglycerides
- The ratio vitamin E/plasma triglycerides reflects the oxidative stress to which an organism has been subjected. The smaller the value of this ratio the greater the level of oxidative stress.
- Measurement of the plasma triglyceride concentrations was carried out using enzymatic methods according to the recommendations of the supplier (Biotrol, Paris, France). A polyvalent control serum (Biotrol-33-plus) was treated at the same time as the samples in order to check the precision of the results of the plasma analysis.
- The plasma concentrations of vitamin E were determined by reversed-phase high performance liquid chromatography on a Kontron series 400 device (Kontron St Quentin en Yvelines, France) using a hexane extract. α-tocopherol acetate (Sigma) was added to the samples as internal control. The samples were extracted twice with hexane after precipitation of the proteins with ethanol. The extract was dried under nitrogen, dissolved in an ethanol-methylene chloride mixture (65:35, v/v) and injected onto a C18 column (Nucleosil; 250 mm long, i.d. 46 mm., 5 μm particles). Pure methanol allowed elution of the α-tocopherol in 5 minutes and the tocopherol acetate in 6.3 minutes at a flow rate of 2 ml/min. The compounds were detected by UV (292 nm) then quantified with internal and external calibrations using control solutions.
- The obtained results are shown in the following table:
Diet Anovaa Starch Fructose Starch + FOS Fructose + FOS Sugar FOS Sugar × FOS Triglycerides (TG) 1.76 ± 0.21 3.73 ± 0.45 1.47 ± 0.11 2.49 ± 0.26 <0.001 <0.05 NS nmol/ml Vitamin E 9.01 ± 0.54 9.74 ± 0.92 7.21 ± 0.35 8.74 ± 0.62 NS <0.05 NS μg/ml Vitamin E/TG 5.98 ± 0.93 2.68 ± 0.12 5.03 ± 0.29 3.95 ± 0.61 <0.001 NS NS μg/mol TG
The results are the averages calculated for 10 animals ± standard deviation.
avalue of p for the ANOVA. The results of the ANOVA are significant for p < 0.05, NS. not significant
- In contrast to the starch diet, the diet rich in fructose lowers the ratio Vitamin E/TG, which proves the existence of oxidative stress.
- The supplementation with FOS prevents the lowering of this ratio, in other words reduces the oxidative stress which results from consumption of a diet rich in fructose.
- Busserolles J., Rock E., Gueux E., Mazur A., Grolier P. and Rayssiguier Y., 2002a. Short term consumption of a high sucrose diet has a pro-oxydant effect in rats. Brit. J. Nutr., 87(4): 337-342.
- Busserolles J., Gueux E., Rock E., Mazur A. and Rayssiguier Y., 2002b. Substituting honey for refined carbohydrates protects against the pro-oxydant effect of a high fructose diet. J. Nutr., 132(11): 3379-82.
- Lee H. S., Shoeman D. W. and Csallany A. S., 1992. Urinary response to in vivo lipid peroxydation induced by vitamin E deficiency. Lipids, 27: 124-128.
- Okhawa H., Ohishi N. and Yagi K., 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95: 351-358.
- Rayssiguier Y., Gueux E., Bussiere L., and Mazur A., 1993. Copper deficiency increases the suceptibility of lipoproteins and tissues to peroxidation in rats. J. Nutr. 123: 1343-1348.
Claims (10)
1. A method of treatment for preventing or treating oxidative stress, comprising the use of prebiotics for the preparation of food preparations, functional foods, or pharmaceutical compositions.
2. The method of claim 1 , comprising the use of at least one oligosaccharide chosen from:
fructans
fructooligosaceharides (FOS)
galactooligosaccharides
xylooligosaccharides
soybean oligosaccharides
gentiooligosaccharides
isomaltooligosaccharides
3. The method of claim 1 , comprising the use of fructooligosaccharides (FOS) of general formula Glucosyl-(Fructosyl)n-Fructose or (Fructosyl)m-Fructose where n represents an integer from 1 to 8, in particular from 1 to 5, and m represents an integer from 1 to 8, in particular from 1 to 5, such as the short-chain FOS, 1 -kestose, nystose or fructosylnystose.
4. The method of claim 1 , in the context of the prevention or treatment of oxidative stress linked to the consumption of sugars.
5. The method of claim 1 , in the context of the prevention or treatment of oxidative stress linked to the consumption of fructose.
6. The method of claim 1 , in the context of the prevention or treatment of oxidative stress which is due to a consumption of fructose in food greater than approximately 50 g/day on average.
7. The method of claim 1 , in which said prebiotics are administered at a daily dose of approximately 1 g to approximately 20 g, in particular approximately 2 g to approximately 17 g, in particular approximately 5 g to approximately 15 g.
8. The method of claim 1 , as compounds with an anti-radical effect in the context of the prevention or treatment of oxidative stress.
9. The method of claim 1 , as compounds with an anti-ageing effect linked to an effect which protects the cells of the organism against the action of free radicals.
10. A food preparation comprising a mixture of fructooligosaccharides (FOS), as defined in claim 3 , comprising 64% Glucosyl-(Fructosyl)n-Fructose and 36% (Fructosyl)m-Fructose, with average degrees of polymerization of 4.8, the proportion by weight of said FOS present in said preparation varying between 10% and 100%, and in particular being approximately 15% to approximately 35%, preferably approximately 20%, relative to the quantity of fructose present in said preparation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR02/16136 | 2002-12-18 | ||
FR0216136A FR2848783B1 (en) | 2002-12-18 | 2002-12-18 | USE OF PREBIOTICS FOR PREVENTING OR TREATING OXIDIZING STRESS |
PCT/FR2003/003770 WO2004056210A1 (en) | 2002-12-18 | 2003-12-17 | Use of prebiotics for preventing or treating oxidation stress |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060252725A1 true US20060252725A1 (en) | 2006-11-09 |
Family
ID=32406181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/539,632 Abandoned US20060252725A1 (en) | 2002-12-18 | 2003-12-17 | Use of prebiotics for preventing or treating oxidation stress |
Country Status (7)
Country | Link |
---|---|
US (1) | US20060252725A1 (en) |
EP (1) | EP1571926A1 (en) |
JP (1) | JP2006510703A (en) |
AU (1) | AU2003300651A1 (en) |
CA (1) | CA2510766A1 (en) |
FR (1) | FR2848783B1 (en) |
WO (1) | WO2004056210A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120245123A1 (en) * | 2011-03-21 | 2012-09-27 | Abbott Laboratories | Methods for improving bone health in infants using prebiotics |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013126015A1 (en) * | 2012-02-23 | 2013-08-29 | N. V. Nutricia | Composition comprising non- digestible oligosaccharides |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5502180A (en) * | 1993-08-10 | 1996-03-26 | Su/ dzucker AG Mannheim/Ochsenfurt | Inulin derivatives, process for their preparation and their use |
US5721345A (en) * | 1994-06-14 | 1998-02-24 | Raffinerie Tirlemontoise, S.A. | Prevention of mammary carcinogenesis and breast cancer treatment |
US6500805B2 (en) * | 1997-05-20 | 2002-12-31 | Tiense Suikerraffinaderij N.V. | Fructan containing composition for the prevention and treatment of colon cancer and method for the prevention and treatment of same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3579128B2 (en) * | 1995-05-31 | 2004-10-20 | 明治製菓株式会社 | Lipid peroxide rise inhibitor |
DE19817877C2 (en) * | 1998-04-22 | 2002-06-13 | Hans Guenter Berner | Energy drink based on fruit juice |
EP1125507A1 (en) * | 2000-02-15 | 2001-08-22 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Inulin products with improved nutritional properties |
US6774111B1 (en) * | 2000-03-14 | 2004-08-10 | Abbott Laboratories | Carbohydrate system and a method for providing nutrition to a diabetic |
EP1174118A1 (en) * | 2000-06-28 | 2002-01-23 | Cognis France S.A. | Use of inulin and derivatives thereof |
EP1175905A1 (en) * | 2000-07-24 | 2002-01-30 | Societe Des Produits Nestle S.A. | Nutritional Composition |
DE20106845U1 (en) * | 2001-04-19 | 2001-11-08 | Rats Apotheke Dr Wolfgang Albr | Liqueur for diabetics |
US20030004211A1 (en) * | 2001-05-25 | 2003-01-02 | Frank Corsini | Carbohydrate modifying agent and drinks containing the modifying agent |
NL1033521C2 (en) * | 2007-03-08 | 2008-09-09 | Friesland Brands Bv | Children's foods with optimized amino acid composition. |
-
2002
- 2002-12-18 FR FR0216136A patent/FR2848783B1/en not_active Expired - Fee Related
-
2003
- 2003-12-17 US US10/539,632 patent/US20060252725A1/en not_active Abandoned
- 2003-12-17 CA CA002510766A patent/CA2510766A1/en not_active Abandoned
- 2003-12-17 WO PCT/FR2003/003770 patent/WO2004056210A1/en active Application Filing
- 2003-12-17 JP JP2004561561A patent/JP2006510703A/en active Pending
- 2003-12-17 AU AU2003300651A patent/AU2003300651A1/en not_active Abandoned
- 2003-12-17 EP EP03813628A patent/EP1571926A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5502180A (en) * | 1993-08-10 | 1996-03-26 | Su/ dzucker AG Mannheim/Ochsenfurt | Inulin derivatives, process for their preparation and their use |
US5721345A (en) * | 1994-06-14 | 1998-02-24 | Raffinerie Tirlemontoise, S.A. | Prevention of mammary carcinogenesis and breast cancer treatment |
US6500805B2 (en) * | 1997-05-20 | 2002-12-31 | Tiense Suikerraffinaderij N.V. | Fructan containing composition for the prevention and treatment of colon cancer and method for the prevention and treatment of same |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120245123A1 (en) * | 2011-03-21 | 2012-09-27 | Abbott Laboratories | Methods for improving bone health in infants using prebiotics |
Also Published As
Publication number | Publication date |
---|---|
CA2510766A1 (en) | 2004-07-08 |
WO2004056210A1 (en) | 2004-07-08 |
FR2848783A1 (en) | 2004-06-25 |
AU2003300651A1 (en) | 2004-07-14 |
JP2006510703A (en) | 2006-03-30 |
FR2848783B1 (en) | 2005-05-13 |
EP1571926A1 (en) | 2005-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Aleixandre et al. | Dietary fiber and blood pressure control | |
EP1455605B1 (en) | Soft drink replacer | |
ZA200504385B (en) | Prebiotic compositions | |
TW201208583A (en) | Nutritional compositions | |
US6500805B2 (en) | Fructan containing composition for the prevention and treatment of colon cancer and method for the prevention and treatment of same | |
EP1861113B1 (en) | Use of an onion extract for making a composition to control weight gain | |
TWI778202B (en) | Use of gallic acid and phenolic compounds other than gallic acid | |
TW202102210A (en) | Composition for intestinal barrier function improvement | |
US20060252725A1 (en) | Use of prebiotics for preventing or treating oxidation stress | |
DE202012101011U1 (en) | Preparation for the nutritive supplement for weight loss | |
CA2399063C (en) | A method for maintaining or improving the synthesis of mucins | |
US6833350B2 (en) | Method for maintaining or improving the synthesis of mucins | |
JP4746281B2 (en) | In vivo lipid regulator | |
Yañez-Sánchez et al. | Bio-functional activities of agavins on health | |
WO2023076572A1 (en) | Nutritional composition for glucose support | |
CN117500388A (en) | Infant nutrition specific to the lactation stage | |
AU776979B2 (en) | Fructan containing composition for the prevention and treatment of colon cancer | |
US20110287145A1 (en) | Nutrition composition containing omega-3 fatty acids and mcts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, FRA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAYSSIGUIER, YVES;BUSSEROLLES, JEROMES;MAZUR, ANDRE;AND OTHERS;REEL/FRAME:018127/0517;SIGNING DATES FROM 20050721 TO 20050819 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |